BridgeBio Pharma develops medicines for patients with genetic diseases, with its main product being Attruby for a heart condition. It last closed at $76.03 on Nov 20, down 2.75% on the day. The next earnings report for BBIO is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, BBIO reported EPS of -$0.42 on revenue of $353.2M, with revenue up 192.6% from a year ago. Over its last 8 reports the stock moved an average of 4.0% the session after earnings. Over the last 12 months BBIO insiders bought $0 of stock on the open market and sold $90.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is BBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BBIO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BBIO · as of the Nov 20 close · updated each morning
Turning up
The stock is 1% above its 20 day and 8% above its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the 100 day average at $75.49, and the nearest resistance the Pivot at $76.58.
Short trendBullish
Long trendNeutral
MomentumNeutral
StretchNormal
VolatilityNormal, 3.4%/day
Key levels
$93.4252 week high+22.9%
$77.69Pivot R1+2.2%
$76.81Swing high (Sep 9)+1.0%
$76.58Pivot+0.7%
$76.03Last close
$75.49100 day average−0.7%
$75.4220 day average−0.8%
$75.02Swing low (Aug 31)−1.3%
$74.91Pivot S1−1.5%
$72.76200 day average−4.3%
$70.3050 day average−7.5%
$62.5052 week low−17.8%
Indicators
RSI (14)
54.90
Middle of its range
Neutral
MACD
2.10
Below its signal line
Bearish
Stochastic
57.0
Middle of its range
Neutral
ADX (14)
36.9
Trending up
Williams %R
-62.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
31.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.3%
Change over 10 sessions
Bullish
ATR (14)
$2.61
Typical daily range, 3.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityLow, 8.1%/day
Key levels
$93.4252 week high+22.9%
$77.69Pivot R1+2.2%
$76.81Swing high (Sep 9)+1.0%
$76.58Pivot+0.7%
$76.03Last close
$75.49100 day average−0.7%
$75.4220 day average−0.8%
$75.02Swing low (Aug 31)−1.3%
$74.91Pivot S1−1.5%
$72.76200 day average−4.3%
$70.3050 day average−7.5%
$62.5052 week low−17.8%
Indicators
RSI (14)
54.36
Middle of its range
Neutral
MACD
0.43
Above its signal line
Bullish
Stochastic
52.9
Middle of its range
Neutral
ADX (14)
24.7
Weak trend
Williams %R
-42.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
15.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+5.0%
Change over 10 sessions
Bullish
ATR (14)
$6.16
Typical daily range, 8.1% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for BBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow BBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BBIOHow many large options trades hit BBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BBIO in the last 90 days.
From SEC Form 4 filings by BBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBIO is in one of them and how their past BBIO trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company based in Palo Alto, California, that develops medicines for people with genetic diseases. Its main commercial product is Attruby, a treatment for a heart condition caused by transthyretin amyloidosis, sold in the United States. The same medicine is sold under another name in Europe and Japan through partners. The company is also developing treatments for other rare conditions, such as achondroplasia and muscular dystrophy, for patients, physicians and healthcare providers.